AnaptysBio (NasdaqGS:ANAB) FY Conference Transcript

AnaptysBio FY Conference Summary Company Overview - Company: AnaptysBio (NasdaqGS:ANAB) - Event: FY Conference on March 04, 2026 - Key Speakers: Daniel Faga, President and CEO Key Points Business Separation - AnaptysBio is separating its biopharma operations from its royalty business, with the separation expected to be completed in the next couple of months [2][4] - The royalty business is projected to generate substantial revenue, particularly from the drug Jemperli, which is on a trajectory of over $1.4 billion in run rate revenue for GSK [4][21] - The separation aims to unlock value for shareholders by allowing investors to focus on either the high-margin royalty business or the biopharma operations [6][10] Financial Projections - Jemperli is expected to generate approximately $200 million in royalties for AnaptysBio this year [4] - The biopharma business will require funding, with estimates suggesting that $100 million would support operations into the second half of 2027, while $200 million would extend this into 2028 [19] - The royalty business is expected to be cash flow positive by the second half of 2027 [18] Jemperli Performance - Jemperli's revenue growth is driven by its competitive edge over Keytruda, particularly in endometrial cancer, with GSK's revenue growth in the mid-teens quarter-over-quarter [21][22] - GSK is expected to receive pivotal trial data for Jemperli in rectal cancer, which could further enhance its market position [22][24] Litigation with GSK - AnaptysBio is involved in litigation with GSK regarding Jemperli, focusing on GSK's alleged breaches of exclusivity obligations and commercial return efforts [28][29] - The litigation is not expected to impact the timing of the business separation [28] Biopharma Operations - The biopharma segment will focus on drugs like ANB033 (a CD122 antagonist) and ANB101 (a BDCA-2 modulator) [5][36] - ANB033 is being developed for celiac disease, targeting inflammation rather than just the antigen, which is a novel approach in this space [37][38] - The company is also exploring the use of ANB033 for Eosinophilic Esophagitis (EoE), leveraging its mechanism of action to target inflammatory pathways [55] Clinical Trials and Opportunities - ANB033 is undergoing trials with results expected by Q4 2026, focusing on mucosal healing in celiac disease patients [39][45] - The target population for ANB033 includes approximately 250,000 patients in the U.S. who are non-responsive to a gluten-free diet [51] - The company is also considering expanding into other indications, such as vitiligo, depending on the success of ongoing trials [59] BDCA-2 Modulator Development - The BDCA-2 modulator is in a Phase 1A trial, with differentiation from competitors being a key focus [60] - The company aims to demonstrate a longer half-life and a better profile compared to existing treatments [61] Conclusion AnaptysBio is strategically positioning itself for growth through the separation of its biopharma and royalty businesses, with a strong focus on innovative drug development and addressing unmet medical needs in celiac disease and EoE. The company is optimistic about its financial outlook and the potential for significant market opportunities in the coming years.